Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), Arcus ...

Fintel reports that on February 26, 2025, HC Wainwright & Co. upgraded their outlook for Arcus Biosciences (NYSE:RCUS) from ...

Universal Health Realty Income Trust announced today that for the three-month period ended December 31, 2024, net income was $4.7 million, or $.34 per diluted share, as compared to $3.6 million, or $.

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its ...

Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The ...

Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

Arcus Biosciences (NYSE:RCUS – Get Free Report) had its price target dropped by equities researchers at HC Wainwright from ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...